OBJECTIVE: DecisionDx-Melanoma * is a 31-gene expression profile test that predicts the risk of metastasis in patients with primary cutaneous melanoma (CM). This study was designed to ascertain clinical management changes determined by the test outcome, which classifies CM patients being at low (Class 1) or high (Class 2) risk for recurrence. RESEARCH DESIGN AND METHODS: Medical charts were reviewed from 156 CM patients from six institutions (three dermatology and three surgical oncology practices) who were consecutively tested between May 2013 and December 2015. Clinical management data that were compiled and compared before and after receipt of the 31-gene expression test result included frequency of physical exams, frequency and modality of imaging, and referrals to surgical and medical oncologists. RESULTS: Forty-two percent of patients were Stage I, 47% were Stage II and 8% were Stage III. Overall, 95 patients (61%) were Class 1 and 61 (39%) were Class 2. Documented changes in management were observed in 82 (53%) patients, with the majority of Class 2 patients (77%) undergoing management changes compared to 37% of Class 1 patients (p < 0.0001 by Fisher's exact test). The majority (77/82, 94%) of these changes were concordant with the risk indicated by the test result (p < 0.0001 by Fisher's exact test), with increased management intensity for Class 2 patients and reduced management intensity for Class 1 patients. CONCLUSIONS: Molecular risk classification by gene expression profiling has clinical impact and influences physicians to direct clinical management of CM patients. The vast majority of the changes implemented after the receipt of test results were reflective of the low or high recurrence risk associated with the patient's molecular classification. Because follow-up data was not collected for this patient cohort, the study is limited for the assessment of the impact of gene expression profile based management changes on healthcare resource utilization and patient outcome.
OBJECTIVE: DecisionDx-Melanoma * is a 31-gene expression profile test that predicts the risk of metastasis in patients with primary cutaneous melanoma (CM). This study was designed to ascertain clinical management changes determined by the test outcome, which classifies CMpatients being at low (Class 1) or high (Class 2) risk for recurrence. RESEARCH DESIGN AND METHODS: Medical charts were reviewed from 156 CMpatients from six institutions (three dermatology and three surgical oncology practices) who were consecutively tested between May 2013 and December 2015. Clinical management data that were compiled and compared before and after receipt of the 31-gene expression test result included frequency of physical exams, frequency and modality of imaging, and referrals to surgical and medical oncologists. RESULTS: Forty-two percent of patients were Stage I, 47% were Stage II and 8% were Stage III. Overall, 95 patients (61%) were Class 1 and 61 (39%) were Class 2. Documented changes in management were observed in 82 (53%) patients, with the majority of Class 2 patients (77%) undergoing management changes compared to 37% of Class 1 patients (p < 0.0001 by Fisher's exact test). The majority (77/82, 94%) of these changes were concordant with the risk indicated by the test result (p < 0.0001 by Fisher's exact test), with increased management intensity for Class 2 patients and reduced management intensity for Class 1 patients. CONCLUSIONS: Molecular risk classification by gene expression profiling has clinical impact and influences physicians to direct clinical management of CMpatients. The vast majority of the changes implemented after the receipt of test results were reflective of the low or high recurrence risk associated with the patient's molecular classification. Because follow-up data was not collected for this patient cohort, the study is limited for the assessment of the impact of gene expression profile based management changes on healthcare resource utilization and patient outcome.
Authors: Gerald Saldanha; Jeremy Yarrow; Jay Pancholi; Katarina Flatman; Kah Wee Teo; Somaia Elsheik; Rebecca Harrison; Marie O'Riordan; Mark Bamford Journal: Am J Surg Pathol Date: 2018-06 Impact factor: 6.394
Authors: Aaron W Kangas-Dick; Alissa Greenbaum; Victor Gall; Roman Groisberg; Janice Mehnert; Chunxia Chen; Dirk F Moore; Adam C Berger; Vadim Koshenkov Journal: Ann Surg Oncol Date: 2021-01-23 Impact factor: 5.344
Authors: Robert W Cook; Brooke Middlebrook; Jeff Wilkinson; Kyle R Covington; Kristen Oelschlager; Federico A Monzon; John F Stone Journal: Diagn Pathol Date: 2018-02-13 Impact factor: 2.644
Authors: Jennifer Keller; Theresa L Schwartz; Jason M Lizalek; Ea-Sle Chang; Ashaki D Patel; Maria Y Hurley; Eddy C Hsueh Journal: Cancer Med Date: 2019-04-05 Impact factor: 4.452
Authors: Kevin Yang; Allen S W Oak; Radomir M Slominski; Anna A Brożyna; Andrzej T Slominski Journal: Int J Mol Sci Date: 2020-05-16 Impact factor: 5.923
Authors: S Podlipnik; C Carrera; A Boada; N A Richarz; J L López-Estebaranz; F Pinedo-Moraleda; M Elosua-González; M M Martín-González; R Carrillo-Gijón; P Redondo; E Moreno; J Malvehy; S Puig Journal: J Eur Acad Dermatol Venereol Date: 2019-02-28 Impact factor: 6.166